EVOKE/EVOKE+

Investigating Semaglutide in People with Early Alzheimer’s Disease

The EVOKE trial is a randomized, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of oral semaglutide in subjects with early Alzheimer’s disease. Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to have potential benefits for reducing cognitive decline and inflammation in preclinical studies and real-world data.

The primary objective of the EVOKE trial is to confirm the superiority of oral semaglutide compared to placebo in the change in cognition and function in subjects with mild cognitive impairment (MCI) or mild dementia of the Alzheimer’s type. The trial will also assess the safety and tolerability of oral semaglutide in this patient population.

Secondary objectives of the trial include evaluating the effect of oral semaglutide on cerebral glucose metabolism, markers of inflammation, and cardiovascular outcomes. The trial will enroll approximately subjects across multiple sites globally and follow them for up to three years.

If the EVOKE trial demonstrates significant benefits of oral semaglutide in reducing cognitive decline and improving function in early Alzheimer’s disease, it could provide a new treatment option for patients with this devastating condition.

EVOKE and EVOKE Plus are almost identical in design but considered different studies due to the latter allowing for cerebral vascular changes as part of the inclusion criteria.